ArticleJournal of experimental & clinical cancer research : CR2023

CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.

Tsutomu Nakazawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.